US4916239A
(en)
*
|
1988-07-19 |
1990-04-10 |
Merck & Co., Inc. |
Process for the lactonization of mevinic acids and analogs thereof
|
GB9007738D0
(en)
*
|
1990-04-05 |
1990-06-06 |
British Bio Technology |
Compounds
|
US5223415A
(en)
*
|
1990-10-15 |
1993-06-29 |
Merck & Co., Inc. |
Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
|
US5250435A
(en)
*
|
1991-06-04 |
1993-10-05 |
Merck & Co., Inc. |
Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
|
AU660132B2
(en)
*
|
1992-12-21 |
1995-06-08 |
Bayer Aktiengesellschaft |
Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
|
EP0680320B1
(en)
*
|
1993-01-19 |
1999-04-14 |
Warner-Lambert Company |
Stable oral ci-981 formulation and process of preparing same
|
IN186879B
(xx)
*
|
1997-10-28 |
2001-12-01 |
Ranbaxy Lab Ltd |
|
IN186880B
(xx)
*
|
1997-10-28 |
2001-12-01 |
Ranbaxy Lab Ltd |
|
ZA9810764B
(en)
*
|
1998-04-22 |
1999-08-13 |
Ranbaxy Lab Ltd |
An improved process of lactonization in the preparation of statins.
|
CA2240983A1
(en)
|
1998-06-18 |
1999-12-18 |
Yong Tao |
Process to manufacture simvastatin and intermediates
|
CN1122029C
(zh)
*
|
1998-12-10 |
2003-09-24 |
钟渊化学工业株式会社 |
制备辛伐他汀的方法
|
SK282679B6
(sk)
*
|
1999-04-16 |
2002-11-06 |
Biotika, A. S. |
Spôsob izolácie lovastatínu z vyfermentovanej pôdy
|
WO2001000606A1
(en)
*
|
1999-06-29 |
2001-01-04 |
Kaneka Corporation |
Process for selective lactonization
|
US6380401B1
(en)
|
1999-10-27 |
2002-04-30 |
Merck & Co., Inc. |
Lactonization process
|
KR20030069790A
(ko)
|
2000-03-03 |
2003-08-27 |
비오갈 기오기스제르갸르 알티. |
이량체 불순물의 농도가 저하된 로바스타틴 및심바스타틴의 정제 방법
|
NL1017548C2
(nl)
|
2001-03-09 |
2002-09-10 |
Synthon Bv |
Een lactonisatie proces.
|
US6797831B2
(en)
*
|
2001-05-18 |
2004-09-28 |
Aurobindo Pharma Limited |
Process for lactonization to produce simvastatin
|
KR100407758B1
(ko)
*
|
2001-08-27 |
2003-12-01 |
씨제이 주식회사 |
스타틴의 제조에 있어서 락톤화 방법
|
KR100502834B1
(ko)
*
|
2002-03-25 |
2005-07-20 |
보령제약 주식회사 |
개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법
|
AU2003226051A1
(en)
*
|
2002-04-16 |
2003-11-03 |
Banyu Pharmaceutical Co., Ltd. |
Solid forms of salts with tyrosine kinase activity
|
AR040588A1
(es)
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
CA2508840A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
CA2515179A1
(en)
|
2003-02-11 |
2004-08-26 |
Ferenc Korodi |
Process for preparing simvastatin having controlled ranges of simvastatin dimer content
|
CA2535359A1
(en)
|
2003-08-21 |
2005-03-03 |
Merck Frosst Canada Ltd. |
Cathepsin cysteine protease inhibitors
|
US7829552B2
(en)
|
2003-11-19 |
2010-11-09 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyromimetics
|
DE602004017784D1
(de)
*
|
2004-03-30 |
2008-12-24 |
Lupin Ltd |
Verbessertes verfahren zur herstellung von 4-hydroxypyran-2-onderivaten
|
US7678927B2
(en)
*
|
2004-09-08 |
2010-03-16 |
Jubilant Organosys Limited |
Process for lactonization in the preparation of statins
|
CA2581596A1
(en)
*
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinations of substituted azetidonones and cb1 antagonists
|
WO2006059346A2
(en)
*
|
2004-12-01 |
2006-06-08 |
Morepen Laboratories Limited |
An improved process for lactonization to produce highly pure statins
|
CA2590860C
(en)
|
2004-12-09 |
2011-05-03 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
DK1855674T3
(da)
|
2005-03-02 |
2014-10-20 |
Merck Sharp & Dohme |
Sammensætning til hæmning af cathepsin k
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
EP1741427A1
(en)
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Pharmaceutical composition comprising simvastatin and ezetimibe
|
WO2007020079A2
(en)
*
|
2005-08-17 |
2007-02-22 |
Synthon B.V. |
Orally disintegratable simvastatin tablets
|
TWI387592B
(zh)
*
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
US20070117996A1
(en)
*
|
2005-11-21 |
2007-05-24 |
Srinivasulu Gudipati |
Process for preparing simvastatin
|
MX2008008340A
(es)
*
|
2005-12-21 |
2008-09-03 |
Schering Corp |
Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
|
PE20071162A1
(es)
*
|
2005-12-21 |
2007-11-30 |
Schering Corp |
Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
MX2008013427A
(es)
|
2006-04-19 |
2008-11-04 |
Novartis Ag |
Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
|
US20080103122A1
(en)
*
|
2006-09-05 |
2008-05-01 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
US8173629B2
(en)
|
2006-09-22 |
2012-05-08 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
RS51780B
(en)
|
2007-01-10 |
2011-12-31 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. |
INDASOLS SUBSTITUTED BY AMIDE AS INHIBITORS OF POLY (ADP-Ribose) POLYMERASES (PARP)
|
AU2008221263B2
(en)
|
2007-03-01 |
2012-02-23 |
Novartis Ag |
Pim kinase inhibitors and methods of their use
|
WO2008144062A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
WO2009002495A1
(en)
|
2007-06-27 |
2008-12-31 |
Merck & Co., Inc. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US20090048335A1
(en)
*
|
2007-08-17 |
2009-02-19 |
Venkata Naga Mandava |
Process for preparing simvastatin
|
BRPI0821090B8
(pt)
*
|
2007-12-21 |
2021-05-25 |
Ligand Pharm Inc |
moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
|
CN102089016A
(zh)
*
|
2008-02-27 |
2011-06-08 |
托门医学股份公司 |
植入物及其制备方法
|
EP2204170A1
(en)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Pharmaceutical composition comprising ezetimibe and simvastatin
|
EP2216016A1
(en)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Process for the preparation of a pharmaceutical composition comprising ezetimibe
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
BR112012008849A2
(pt)
|
2009-10-14 |
2015-09-22 |
Schering Corp |
composto, composição farmacêutica, e, uso de um composto
|
CN101704808A
(zh)
|
2009-11-20 |
2010-05-12 |
西南合成制药股份有限公司 |
制备他汀类化合物的内酯化方法
|
CN104098537A
(zh)
*
|
2009-11-20 |
2014-10-15 |
北大医药股份有限公司 |
制备他汀类化合物的内酯化方法
|
EP2368543A1
(en)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
WO2012112363A1
(en)
|
2011-02-14 |
2012-08-23 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JP2014514321A
(ja)
|
2011-04-21 |
2014-06-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
インスリン様増殖因子1受容体阻害剤
|
US9393224B2
(en)
|
2011-08-26 |
2016-07-19 |
Osaka University |
Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2597092A1
(en)
|
2011-11-24 |
2013-05-29 |
Sterling Biotech Limited |
A process for purification of lovastatin
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
MX2015008196A
(es)
|
2012-12-20 |
2015-09-16 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
CA2923272A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
EP3094323A4
(en)
|
2014-01-17 |
2017-10-11 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
MX2022007535A
(es)
|
2019-12-17 |
2022-09-23 |
Merck Sharp & Dohme Llc |
Inhibidores de prmt5.
|